Gilead Sciences, Inc. (GILD)

65.01 +0.66 (+1.03%) At close: 04:00PM EDT

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000
https://www.gilead.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 14,400

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Daniel P. O'Day	Chairman & CEO	6.09M	N/A	1964
Mr. Andrew D. Dickinson	Exec. VP & CFO	2.55M	N/A	1970
Mr. Brett A. Pletcher	Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.	2.47M	N/A	1969
Ms. Johanna Mercier	Chief Commercial Officer	2.92M	N/A	1970
Dr. Merdad V. Parsey M.D., Ph.D.	Chief Medical Officer	2.68M	N/A	1963
Ms. Diane E. Wilfong	Sr. VP, Corp. Controller & Chief Accounting Officer	N/A	N/A	1962
Ms. Jacquie Ross C.F.A.	VP of Investor Relations	N/A	N/A	N/A
Ms. Jyoti K. Mehra	Exec. VP of HR	N/A	N/A	N/A
Dr. Taiyin Yang Ph.D.	Exec. VP of Pharmaceutical Devel. & Manufacturing	N/A	N/A	1954
Dr. Michael Quigley Ph.D.	Sr. VP of Research Biology	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Corporate governance

Gilead Sciences, Inc.’s ISS governance QualityScore as of 1 May 2022 is 1. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.